Harry Erba, MD, PhD:In looking at her presenting symptoms, physical exam, and blood counts, this is not at all atypical for patients. And in fact, patients like this may be seen by a number of specialists and primary care physicians before they actually get to the hematologist. So, if a blood count isn’t checked and they’re having abdominal fullness, night sweats, prurituswhich is quite common—or fatigue, a number of evaluations for other disorders might have ensued before finally getting to the blood count and showing that the problem is in the bone marrow. So, this is quite typical.
Now the natural history of myelofibrosis is quite varied. Some patients having a very long survival, and some much shorter. And a number of prognostic staging evaluations, or models, have been developed. The first that we’ve been using is Cervantes’ International Prognostic Score criteria, where there are 5 prognostic factors: age over the age of 65, which she has; presence of constitutional symptoms such fevers, night sweats, and weight loss, which she has; anemia with a hemoglobin under 10; leukocytosis with a white-blood cell count over 25,000; and the presence of more than 1% circulating blast. That’s the only one we don’t know that she has, but she has all of the other 4.
If you have none of those factors, then you have low-risk disease with a median survival that exceeds 10 years. However, most patients, 90% of patients, will have intermediate 1risk disease with 1 risk factor, intermediate-2 with 2 risk factors, or high-risk disease with 3 or more risk factors. The median survival gets progressively worse with each of those. For patients with high-risk disease, the median survival is only about 2 years.
Transcript edited for clarity.
March 2017
Participants Discuss Treating a Patient With Myelofibrosis and Anemia
March 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.
Read More
Challenges of Interpreting JAK Inhibitor Data for Real-World Myelofibrosis Care
March 4th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.
Read More